Moderna Shares Rise 12% June 26, Up 125.51% Since January

Moderna (NASDAQ: MRNA) shares closed up 12% on Friday, June 26, extending gains to 125.51% since January. The rally follows an FDA Vaccines and Related Biological Products Advisory Committee 9-0 vote on June 18 that mFLUSIVA (mRNA-1010) has a favorable benefit-risk profile for adults 50 and older, according to BeInCrypto, ahead of an Aug. 5 PDUFA decision date. Piper Sandler lifted its price target to $77 and Jefferies raised its target to $53 while keeping a Hold rating; the consensus target is $43.45. Moderna also restructured around vaccines, oncology and rare diseases and highlighted its pipeline at a June 25 Science Day.